17 Mar 2015

Cyklokapron Tablets (Tranexamic acid) - United Kingdom

ATC: B02AA
BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
ANTIFIBRINOLYTICS
AMINO ACIDS
Cyklokapron Tablets

Generic Matches for Tranexamic acid (1)
Cyklokapron Injection

Last Updated on 17 Mar 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Cyklokapron Tablets Indication

Short-term use for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis as occurs in the following conditions:

- Prostatectomy and bladder surgery

- Menorrhagia

- Epistaxis

- Conisation of the cervix

- Traumatic hyphaema

- Hereditary angioneurotic oedema

- Management of dental extraction in haemophiliacs

 

Cyklokapron Tablets Generic Name

Tranexamic acid

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - Cyklokapron 500 mg Film-coated Tablets (external site)

Related Learning Zones

CSU Knowledge Centre and CME

CSU Knowledge Centre and CME

This Knowledge Centre is intended for allergists, immunologists, dermatologists and other healthcare professionals involved in the treatment and management of Chronic Spontaneous Urticaria (CSU). In the Knowledge Centre, you will find a disease overview, symposium highlights platform, video channel and additional resources including an events calendar and useful external links. This resource has been given a whole new look and feel, intended to improve accessibility and visual appeal. Recent content additions include a frequently asked questions section, case studies from urticaria experts Professor Christian Vestergaard and Professor Torsten Zuberbier and information on the TARGET My Hives app.

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Cyklokapron Tablets Marketing Information

Cyklokapron Tablets Generic Name
Tranexamic acid
Marketing Company
Meda Pharmaceuticals Ltd
Drug Type
POM
Date of Issue, Marketing Authority 01/01/1983

Related Drugs - Haematology

Back to top